Celltrion applies for approval in Europe for eye treatment biosimilar

Based on the results of Phase 3 clinical trials CT-P42, biosimilar of Eylea, the company submitted an application to EMA

Celltrion applies for approval in Europe for eye treatment biosimilar
Dae-Kyu Ahn 1
2023-11-24 12:03:53 powerzanic@hankyung.com
Bio & Pharma

South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it applied for approval from the European Medicines Agency (EMA) for CT-P42, a biosimilar of the eye treatment Eylea (ingredient Aflibercept)

Based on the results of Phase 3 clinical trials worldwide of CT-P42, Celltrion applied with the EMA for approval of Eylea for wet macular degeneration (wAMD), central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO), diabetic macular edema (DME), and myopic choroidal neovascularization (mCNV). 

Developed by Regeneron of the US, Eylea is a blockbuster drug with global sales last year of $9.75 billion. Its exclusive rights in the US expire in May next year and its patents in Europe in November 2025.

Previously, Celltrion verified CT-P42's equivalence to Eylea through a Phase 3 clinical trial with 348 patients suffering from diabetic macular edema in 13 countries, such as the Czech Republic, Hungary, Poland, and Spain.

"Following the favorable results from the global Phase 3 clinical trials for CT-P42, we have finalized the licensing applications for key markets, including the US, South Korea, and Europe," a Celltrion source said. "Our preparations to enter the global market are on track. We plan to keep expanding our product range and incrementally increase our global market influence."

Write to Dae-Kyu Ahn at powerzanic@hankyung.com
#Celltrion #Eylea #biosimilar #CT-P42 #eye treatment #European Medicines Agency #EMA

Celltrion to supply Remsima to Brazil gov’t in three-year row

Celltrion to supply Remsima to Brazil gov’t in three-year row

Celltrion Healthcare's Remsima South Korea's Celltrion Healthcare Co. announced on Friday its autoimmune disease treatment Remsima (ingredient: infliximab) has won a bid for the Brazilian federal government for three consecutive years. The company is set to supply 360,000 vials of Remsima

Celltrion enjoys record earnings on healthy biosimilar biz

Celltrion enjoys record earnings on healthy biosimilar biz

Celltrion's plant in South Korea South Korean pharmaceutical giant Celltrion Inc. logged record quarterly earnings on the strong performance of its key biosimilar products while expecting its merger with sales affiliates to help the group meet long-term targets.Celltrion Inc. said on Tuesday it

Celltrion’s approved merger removes hurdle to three-way combination

Celltrion’s approved merger removes hurdle to three-way combination

Celltrion founder and Chairman Seo Jung-jin reveals the company's business strategy at its shareholders meeting where its merger with Celltrion Healthcare was approved South Korea’s biosimilar drugmaker Celltrion group on Monday moved one step closer to the planned combination of its thre

Celltrion applies for approval in US for eye treatment biosimilar

Celltrion applies for approval in US for eye treatment biosimilar

South Korean biopharmaceutical company Celltrion Inc. on Friday said it applied for approval from the US Food and Drug Administration (FDA) for CT-P42, a biosimilar of the eye treatment Eylea.Based on the results of Phase 3 clinical trials worldwide of CT-P42, Celltrion applied with the FDA fo
(* comment hide *}